Novanta

Consolidated Statements of Operations
(Amounts in thousands, except per share amounts)
(Unaudited)

	December 31, 2024	March 28, 2025	June 27, 2025	September 26, 2025	December 31, 2025	April 3, 2026	July 3, 2026	October 2, 2026
Revenue	$ 238,060	$ 233,366	$ 241,049	$ 247,836	$ 258,349	$ 257,707	$ 265,807	$ 305,008
Cost of revenue	129,835	129,012	134,303	136,915	145,086	144,129	144,892	169,370
Gross profit	108,225	104,354	106,746	110,921	113,263	113,578	120,915	135,638
Operating expenses:								
Research and development and engineering	25,285	23,238	25,289	24,090	22,867	23,251	23,968	26,347
Selling, general and administrative	43,301	45,596	47,103	51,378	51,582	54,409	59,972	57,615
Amortization of purchased intangible assets	6,548	5,554	6,871	6,928	8,124	5,774	6,415	14,679
Restructuring, acquisition, and related costs	6,384	(2,455)	12,572	6,677	5,858	2,605	12,499	23,086
Total operating expenses	81,518	71,933	91,835	89,073	88,431	86,039	102,854	121,727
Operating income	26,707	32,421	14,911	21,848	24,832	27,539	18,061	13,911
Interest income (expense), net	(6,890)	(5,644)	(5,815)	(6,014)	(3,999)	(1,843)	(1,106)	(8,284)
Foreign exchange transaction gains (losses), net	1,200	(368)	(2,744)	14	908	731	(801)	659
Other income (expense), net	(222)	9	(563)	(90)	(64)	(73)	(256)	60
Income before income taxes	20,795	26,418	5,789	15,758	21,677	26,354	15,898	6,346
Income tax provision (benefit)	4,331	5,210	1,292	5,105	4,206	5,255	3,357	4,329
Net income	$ 16,464	$ 21,208	$ 4,497	$ 10,653	$ 17,471	$ 21,099	$ 12,541	$ 2,017
Earnings per common share:								
Basic	$ 0.46	$ 0.59	$ 0.12	$ 0.30	$ 0.46	$ 0.52	$ 0.31	$ 0.05
Diluted	$ 0.46	$ 0.59	$ 0.12	$ 0.30	$ 0.45	$ 0.51	$ 0.30	$ 0.05
Weighted average common shares outstanding—basic	35,980	36,024	36,022	35,967	38,237	40,425	41,009	42,590
Weighted average common shares outstanding—diluted	36,148	36,130	36,076	36,040	38,681	41,158	41,164	42,709

Adjusted EBITDA (Non-GAAP):

Net Income (GAAP)	$ 16,464	$ 21,208	$ 4,497	$ 10,653	$ 17,471	$ 21,099	$ 12,541	$ 2,017
Interest (income) expense, net	6,890	5,644	5,815	6,014	3,999	1,843	1,106	8,284
Income tax provision	4,331	5,210	1,292	5,105	4,206	5,255	3,357	4,329
Depreciation and amortization	14,363	13,563	15,581	15,711	17,077	14,160	14,648	27,449
Share-based compensation	4,635	7,100	7,498	6,698	8,242	9,796	9,836	10,065
Restructuring, acquisition and related costs	6,376	(3,106)	12,091	6,156	5,302	2,098	11,438	22,243
Inventory related charges associated with a product line closure	-	-	65	-	-	-	-	-
Inventory acquistion fair value adjustments	-	-	-	-	-	-	-	800
Officer transition costs	-	-	-	1,137	-	-	-	-
Planning and design phase of the financial and operation system implementation	-	-	1,693	3,519	2,392	2,658	2,204	3,686
Costs incurred for insurance recovery claim	-	-	324	3,042	2,854	-	3,368	221
Operational transformation costs	-	-	-	-	-	556	797	921
EU medical device regulation charges	-	-	-	-	-	269	378	1,047
Other, net	(978)	359	3,307	76	(844)	(658)	1,057	(719)
Adjusted EBITDA (Non-GAAP)	$ 52,081	$ 49,978	$ 52,163	$ 58,111	$ 60,699	$ 57,076	$ 60,730	$ 80,343